Live Last read · last published · next check
Activist investor Sessa Capital has taken a sizeable stake in long-term, implantable CGM company Senseonics (NYSE: SENS), according to an SEC Schedule 13G filed today. The SEC filing lists Sessa directly owning 4,437,532 shares of Senseonics common stock, with warrants to buy another 8,000,000 shares of stock subject to a 9.9% blocker provision that prevents investors from […] The post Senseonics…
Abbott (NYSE: ABT) is turning to Google’s artificial intelligence expertise to leverage more glucose insights for users of the Abbott Park, Illinois–based life science giant’s Lingo biowearable. Under a multiyear agreement announced today, ongoing glucose insights from Abbott’s Lingo biowearable will combine with Google Health’s technology to provide a more comprehensive view of people’s health.…
Julia Rock-Torcivia Embecta Corp. (Nasdaq: EMBC) raised its full-year outlook for adjusted earnings per share as third-quarter results beat analyst estimates. The medtech company, a BD spinoff that specializes in insulin delivery, reported last week net income of $21.1 million, or $0.36 per share, on revenue of $271.7 million for the three months ended June […] The post Embecta Q3 results beat…
Julia Rock-Torcivia ICU Medical (Nasdaq: ICUI) reported second quarter results that beat Wall Street expectations, upping its full-year guidance. San Clemente, California–based ICE Medical, which specializes in IV therapy, infusion pumps and closed-system drug transfer devices, reported income of $19.1 million, or 76¢ per share, on revenue of $551.7 million for the three months ended June […] The…
Senseonics (NYSE:SENS) stock is up more than 26% today after it reported what CEO Tim Goodnow described as the strongest quarter in the implantable, long-term CGM company’s history. BTIG analysts Marie Thibault, Alexandra Pang, and Sam Eiber noted that the European commercial transition from Ascensia Diabetes Care closed in June across all four markets, bringing […] The post Senseonics more than…
You may already know a lot of the names that are considered leaders of the diabetes technology industry. The likes of Abbott and Dexcom are leaders in the continuous glucose monitor (CGM) space. MiniMed, Insulet and Tandem Diabetes Care are a few of the companies with a significant share in the automated insulin delivery (AID) […] The post 6 diabetes tech companies you need to know appeared first…
Tandem Diabetes Care (Nasdaq: TNDM) says U.S. sales of its insulin pumps were boosted by a scaled pay-as-you-go reimbursement model that’s been rolling out this year. According to the San Diego–based company’s second-quarter report, released after market close yesterday, the alternative reimbursement structure, available through patients’ pharmacy benefits rather than medical benefits, eliminates…
Over the last year, a lot has changed in the diabetes technology space. Does that ring true for the rankings of the space’s largest companies? Within the last 12 months, we’ve seen one of the industry’s biggest players separate from its parent company. We’ve also seen significant regulatory milestones, product launches and unveilings of next-generation […] The post The 10 largest diabetes tech…
Last year, MassDevice and Drug Delivery Business News rolled out the first edition of their Diabetes Technology Innovations Special Report. Now, we have the second edition available for free download, providing an in-depth overview of where the diabetes industry currently stands after another year of innovation and growth. The diabetes tech industry delivers some of the most advanced combinations…
Insulet (Nasdaq:PODD) slightly lowered its 2026 sales growth guidance despite second-quarter results that handily beat Wall Street estimates. The company previously projected total annual sales growth between 21% and 23%. However, it lowered that outlook by 1 percentage point at each end to 20%-22%. The company did increase its adjusted EPS guidance, though, expecting growth […] The post Insulet…
